MediciNova (MNOV) Stock Rockets On COVID-19 Vaccine News

MediciNova MNOV Stock News

MediciNova, Inc. (NASDAQ: MNOV) is making a run for the top in the premarket hours this morning, and for good reason. The company announced positive preclinical data surrounding its COVID-19 vaccine candidate. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

MNOV Heads Up On COVID-19 Vaccine News

As mentioned above, MediciNova is headed for the top in the market this morning after announcing positive COVID-19 news. The comapny said that its intranasal SARS-CoV-2 vaccine prototype for COVID-19 successfully induced systemic serum IgG and mucosal IgA neutralizing antibodies against the S1 antigen of SARS-CoV-2 in mice.

In the release, MNOV said that a mouse model was conducted to assess systemic IgG and mucosal IgA antibody production against S1 Ag after intranasal vaccination with the comapny’s vaccine candidate.

In doing so, the company confirmed a high IgA antibody titer against S1 Ag in the nasal lavage fluid from mice given the vaccine candidate.

In a statement, Yuichi Iwaki, M.D., Ph.D., President and CEO at MNOV, had the following to offer:

We are very encouraged that our intranasal BC-PIV SARS-CoV-2 vaccine induced high titers of systemic serum IgG and mucosal IgA neutralizing antibodies in a mouse model study. These successful results support the scientific and technical rationale of our intranasal vaccine in addition to similar success with BioComo’s BC-PIV RSV vaccine prototype. We look forward to reporting additional progress on our intranasal COVID-19 vaccine in the near future.

Final Thoughts

The news released by MediciNova this morning proved to be overwhelmingly positive. The fact of the matter is that while the focus has been developing a vaccine quickly, in order to combat COVID-19, we need multiple vaccine and treatment options.

The fact that MNOV has produced positive data, suggesting that its vaccine candidate is efficacious, is overwhelmingly positive. Should data continue to go well, the company may have an effective vaccine candidate, that based on the type of virus that leads to COVID-19, will be in demand for years to come.

All in all, MNOV stock is one to pay close attention to ahead.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.